drugset / Trial / NCT06425302

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

NCT06425302

Phase 2 Active not recruiting 90 enrolled Celgene Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

Timeline

Start
2024-08-30
Primary completion
2026-11-23
Completion
2028-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule
Subject Cyclophosphamide Other / unclassified
Subject Doxorubicin Other / unclassified
Subject Golcadomide Other / unclassified
Subject Prednisone Other / unclassified
Subject Vincristine Small molecule
Background Rituximab Monoclonal antibody

Indications